Edwards Lifesciences Corporation (NYSE:EW) Set to Announce Quarterly Earnings on Monday
Edwards Lifesciences Corporation (NYSE:EW) is set to post its quarterly earnings results after the market closes on Monday, July 24th. Analysts expect Edwards Lifesciences Corporation to post earnings of $0.88 per share for the quarter. Edwards Lifesciences Corporation has set its Q2 guidance at $0.82-0.92 EPS and its FY17 guidance at $3.43-3.55 EPS.
Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The firm had revenue of $883.50 million during the quarter, compared to analyst estimates of $776.51 million. During the same quarter in the prior year, the firm earned $0.71 EPS. The business’s revenue for the quarter was up 26.7% compared to the same quarter last year. On average, analysts expect Edwards Lifesciences Corporation to post $3.52 EPS for the current fiscal year and $3.97 EPS for the next fiscal year.
Shares of Edwards Lifesciences Corporation (EW) opened at 116.92 on Monday. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75. The stock has a market cap of $24.53 billion, a price-to-earnings ratio of 38.87 and a beta of 0.63. The stock’s 50 day moving average is $115.58 and its 200 day moving average is $100.62.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/17/edwards-lifesciences-corporation-nyseew-set-to-announce-quarterly-earnings-on-monday.html.
In other Edwards Lifesciences Corporation news, VP Bernard J. Zovighian sold 18,050 shares of the business’s stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $109.21, for a total transaction of $1,971,240.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael A. Mussallem sold 49,100 shares of the business’s stock in a transaction on Friday, April 28th. The stock was sold at an average price of $109.78, for a total value of $5,390,198.00. The disclosure for this sale can be found here. Insiders have sold 252,101 shares of company stock valued at $28,141,680 over the last quarter. 2.13% of the stock is owned by company insiders.
A number of equities research analysts recently commented on the company. BidaskClub raised Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 22nd. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research cut Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, June 8th. Jefferies Group LLC reiterated a “buy” rating and set a $115.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, June 30th. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of Edwards Lifesciences Corporation in a research report on Tuesday, May 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has a consensus rating of “Buy” and an average price target of $121.51.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.